EXHIBIT 10.2
FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT
This FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT, dated as of May 8, 2024 (this “First Amendment”), is an amendment to that certain Securities Purchase Agreement (the “Agreement”) dated as of May 5, 2024, between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages thereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). Capitalized terms used herein but not otherwise defined will have the meanings ascribed to them in the Agreement.
WHEREAS, Section 5.5 of the Agreement provides that it can be amended, and the signatories to this First Amendment constitute the required signatories pursuant to that Section;
WHEREAS, the Company previously approved an Offering of up to $10,000,000 of Securities; and
WHEREAS, the Purchasers and the Company now desire to enter into this First Amendment to reflect certain Purchasers’ additional Subscription Amounts at the Per Share Purchase Price set forth in this Amendment.
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Amendment, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the signatories hereto agree as follows:
| 1. | Certain Purchasers identified on the signature pages hereto have agreed to invest the additional Subscription Amounts as set forth on the signature pages hereto on the same terms and conditions as set forth in the Agreement except that the Per Share Purchase Price shall be $2.158 and the exercise price of the Series A Warrants and Series B Warrants shall be $1.908. |
| 2. | Other than as set forth herein, the Agreement remains in full force and effect. |
| 3. | The provisions of Sections 5.4, 5.8, 5.9, 5.11, 5.12, 5.18, 5.20 and 5.21 of the Agreement shall apply to this Amendment, mutatis mutandis, as if set forth herein. |
[Signature Pages Follow]
1